北京大学医学部机构知识库
Advanced  
IR@PKUHSC  > 北京大学第二临床医学院  > 血液科  > 期刊论文
学科主题: 临床医学
题名:
CXCR4 is a good survival prognostic indicator in multiple myeloma patients
作者: Bao, Li; Lai, Yueyun; Liu, Yanrong; Qin, Yazhen; Zhao, Xiaosu; Lu, Xijing; Jiang, Qian; Lu, Jin; Huang, Xiaojun
关键词: Multiple myeloma ; SDF-1 alpha ; CXCR4 ; Survival ; Bone marrow cells
刊名: LEUKEMIA RESEARCH
发表日期: 2013-09-01
DOI: 10.1016/j.leukres.2013.06.002
卷: 37, 期:9, 页:1083-1088
收录类别: SCI
文章类型: Article
WOS标题词: Science & Technology
类目[WOS]: Oncology ; Hematology
研究领域[WOS]: Oncology ; Hematology
关键词[WOS]: STEM-CELL TRANSPLANTATION ; HIGH-DOSE CHEMOTHERAPY ; IN-SITU HYBRIDIZATION ; PLASMA-CELLS ; GENETIC ABNORMALITIES ; DISEASE PROGRESSION ; C-KIT ; EXPRESSION ; BORTEZOMIB ; PHASE-3
英文摘要:

SDF1 alpha and its receptor CXCR4 are involved in multiple myeloma (MM) by attracting and activating plasma cells in the bone marrow. CXCR4 expression in MM cells is inversely correlated with disease activity. The aim of this study was to evaluate CXCR4 as a prognostic tool in MM, as well as other markers of disease, such as chromosomal aberrancies. Purpose was to investigate the expression levels of SDF-1 alpha before and after bortezomib and thalidomide treatment. From February 2006 to April 2012, CXCR4 expression was prospectively assessed in bone marrow samples from a large population of patients( n = 227) using flow cytometry. Clinical characteristics were collected and chromosomal aberrancies were assessed in 144 patients. SDF-1 alpha levels were determined using ELISA in peripheral blood samples from 40 patients before and after chemotherapy. Our results show that CXCR4 was present in 43.2% (98/227) of newly diagnosed MM patients and that CXCR4 expression was significantly correlated with CD117( P < 0.05). CXCR4-positive MM patients had a significantly longer estimated survival time than CXCR4-negative patients (median of 48 vs. 42 months, P < 0.05). Multivariate survival analyses identified that the +1q21/CXCR4- phenotype is an independent survival predictor, along with the International Staging System (ISS) stage. No significant difference was observed in expression levels of SDF-1 alpha before and after bortezomib/thalidomide treatment. In conclusion, +1q21/CXCR4- could be an independent survival prognosis predictor in MM patients. Expression levels of SDF-1 alpha before and after bortezomib/thalidomidetreatment are not different, although they are higher than in controls. (C) 2013 Published by Elsevier Ltd.

语种: 英语
所属项目编号: Z111107067311070
项目资助者: Beijing Municipal Science and Technology Program
WOS记录号: WOS:000324097600017
Citation statistics:
内容类型: 期刊论文
URI标识: http://ir.bjmu.edu.cn/handle/400002259/63364
Appears in Collections:北京大学第二临床医学院_血液科_期刊论文

Files in This Item:

There are no files associated with this item.


作者单位: Peking Univ, Inst Hematol, Peking Univ Peoples Hosp, Beijing 100871, Peoples R China

Recommended Citation:
Bao, Li,Lai, Yueyun,Liu, Yanrong,et al. CXCR4 is a good survival prognostic indicator in multiple myeloma patients[J]. LEUKEMIA RESEARCH,2013,37(9):1083-1088.
Service
Recommend this item
Sava as my favorate item
Show this item's statistics
Export Endnote File
Google Scholar
Similar articles in Google Scholar
[Bao, Li]'s Articles
[Lai, Yueyun]'s Articles
[Liu, Yanrong]'s Articles
CSDL cross search
Similar articles in CSDL Cross Search
[Bao, Li]‘s Articles
[Lai, Yueyun]‘s Articles
[Liu, Yanrong]‘s Articles
Related Copyright Policies
Null
Social Bookmarking
Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit

Items in IR are protected by copyright, with all rights reserved, unless otherwise indicated.

 

 

Valid XHTML 1.0!
Copyright © 2007-2017  北京大学医学部 - Feedback
Powered by CSpace